Study of soluble Receptor Activator Nuclear Factor Kappa β Ligand (SRANKL) In patients with Bone Metastases

Abstract

Bone metastatic disease is a common complication of malignancy affecting the breast, prostate, lung and kidney. It is a major health problem typically presents with bone pain, pathological fracture or neurological symptoms due to nerve root compression or spinal cord compressiOn. The physician who cares for cancer patients after treatment very often faces the clinical problem of early detection of metastatic lesions without using invasive procedures. Biochemical markers of bone remodeling which are less expensive, less toxic and more accurate methods provide non-invasive means of complementing these techniques The aim of this work was to study the serum level of the soluble form of the receptor activator for nuclear factor (NF)KB (sRANKL) a new bone metabolic marker in patients with bone metastases and compare them with non-metastatic cancer patients in a trial to assess the serum levels of sRANKL as a diagnostic marker in bone micro­ metastases. The studv included 44 subjects divided into three groups:

Group I: Included I 0 apparently healthy individuals as control group.

- Group II: Included 16 patients with carcinoma of the breast, prostate, lung, kidney and colorectum without bone metastases. - Group III: Included 18 patients with carcinoma of the breast, prostate, lung, kidney and colorectum with bone metastases.